Forward Pharma A Stock Return On Equity
| FWPDelisted Stock | USD 2.56 0.00 0.00% |
Forward Pharma A fundamentals help investors to digest information that contributes to Forward Pharma's financial success or failures. It also enables traders to predict the movement of Forward Stock. The fundamental analysis module provides a way to measure Forward Pharma's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Forward Pharma stock.
Forward |
Forward Pharma A Company Return On Equity Analysis
Forward Pharma's Return on Equity or ROE tells company stockholders how effectually their money is being utilized or reinvested. It is a useful ratio when analyzing company profitability or the management effectiveness given the capital invested by the shareholders. ROE shows how efficiently a company utilizes investments to generate income.
Current Forward Pharma Return On Equity | -0.0083 |
Most of Forward Pharma's fundamental indicators, such as Return On Equity, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Forward Pharma A is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
For most industries, Return on Equity between 10% and 30% are considered desirable to provide dividends to owners and have funds for the future growth of the company. Investors should be very careful using ROE as the only efficiency indicator because ROE can be high if a company is heavily leveraged.
CompetitionBased on the latest financial disclosure, Forward Pharma A has a Return On Equity of -0.0083. This is 99.97% lower than that of the Biotechnology sector and 99.98% lower than that of the Health Care industry. The return on equity for all United States stocks is 97.32% lower than that of the firm.
Forward Return On Equity Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Forward Pharma's direct or indirect competition against its Return On Equity to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Forward Pharma could also be used in its relative valuation, which is a method of valuing Forward Pharma by comparing valuation metrics of similar companies.Forward Pharma is currently under evaluation in return on equity category among its peers.
Forward Fundamentals
| Return On Equity | -0.0083 | |||
| Return On Asset | -0.0342 | |||
| Current Valuation | (43.04 M) | |||
| Shares Outstanding | 7.09 M | |||
| Shares Owned By Institutions | 12.90 % | |||
| Number Of Shares Shorted | 4.51 K | |||
| Price To Earning | 0.13 X | |||
| Price To Book | 0.31 X | |||
| EBITDA | (1.89 M) | |||
| Net Income | (1.89 M) | |||
| Cash And Equivalents | 70.77 M | |||
| Cash Per Share | 10.08 X | |||
| Debt To Equity | 0.04 % | |||
| Current Ratio | 117.44 X | |||
| Book Value Per Share | 8.76 X | |||
| Cash Flow From Operations | (2.36 M) | |||
| Short Ratio | 1.78 X | |||
| Earnings Per Share | (0.27) X | |||
| Price To Earnings To Growth | 0.13 X | |||
| Target Price | 37.0 | |||
| Beta | 1.38 | |||
| Market Capitalization | 13.83 M | |||
| Total Asset | 71.41 M | |||
| Retained Earnings | (9.1 M) | |||
| Working Capital | 93.59 M | |||
| Current Asset | 99.8 M | |||
| Current Liabilities | 6.21 M | |||
| Z Score | 1.2 | |||
| Net Asset | 71.41 M |
About Forward Pharma Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Forward Pharma A's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Forward Pharma using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Forward Pharma A based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Pair Trading with Forward Pharma
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Forward Pharma position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Forward Pharma will appreciate offsetting losses from the drop in the long position's value.Moving against Forward Stock
| 0.57 | MMM | 3M Company Fiscal Year End 28th of January 2025 | PairCorr |
| 0.56 | DD | Dupont De Nemours Fiscal Year End 4th of February 2025 | PairCorr |
| 0.52 | MCD | McDonalds Fiscal Year End 3rd of February 2025 | PairCorr |
| 0.49 | IBM | International Business Fiscal Year End 22nd of January 2025 | PairCorr |
| 0.36 | CAT | Caterpillar Fiscal Year End 3rd of February 2025 | PairCorr |
The ability to find closely correlated positions to Forward Pharma could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Forward Pharma when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Forward Pharma - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Forward Pharma A to buy it.
The correlation of Forward Pharma is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Forward Pharma moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Forward Pharma A moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Forward Pharma can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Check out Investing Opportunities to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in housing. You can also try the Odds Of Bankruptcy module to get analysis of equity chance of financial distress in the next 2 years.
Other Consideration for investing in Forward Stock
If you are still planning to invest in Forward Pharma A check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Forward Pharma's history and understand the potential risks before investing.
| Sign In To Macroaxis Sign in to explore Macroaxis' wealth optimization platform and fintech modules | |
| Performance Analysis Check effects of mean-variance optimization against your current asset allocation | |
| Portfolio Center All portfolio management and optimization tools to improve performance of your portfolios | |
| Aroon Oscillator Analyze current equity momentum using Aroon Oscillator and other momentum ratios | |
| Idea Breakdown Analyze constituents of all Macroaxis ideas. Macroaxis investment ideas are predefined, sector-focused investing themes | |
| Commodity Channel Use Commodity Channel Index to analyze current equity momentum | |
| Positions Ratings Determine portfolio positions ratings based on digital equity recommendations. Macroaxis instant position ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
| Piotroski F Score Get Piotroski F Score based on the binary analysis strategy of nine different fundamentals | |
| CEOs Directory Screen CEOs from public companies around the world |